The 'PAI-1 paradox' in vascular remodelling

被引:78
作者
Diebold, Isabel [1 ]
Kraicun, Damir [1 ]
Bonello, Steve [1 ]
Goerlach, Agnes [1 ]
机构
[1] Tech Univ Munich, Deutsch Herzzentrum Munchen, D-80636 Munich, Germany
关键词
Plasminogen activator inhibitors; atherosclerosis; restenosis; remodelling; pulmonary hypertension;
D O I
10.1160/TH08-08-0524
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Vascular remodelling is a complex phenomenon associated with restructuring of the vessel wall as a consequence of disruption of vascular homeostasis. Alterations of the vascular wall have been linked to a variety of cardiovascular disorders including atherosclerosis, vascular injury and pulmonary hypertension. Plasminogen activator inhibitor-1 (PAI-1) is a member of the serpin (serine proteinase inhibitor) family and acts as an important inhibitor of fibrinolysis by interfering with the plasminogen system. In addition to its anti-fibrinolytic effects, PAI-1 appears to modulate cellular responses linked to vascular remodelling. Since PAI-1 levels have been shown to be altered in various disorders associated with vascular remodelling of the systemic and pulmonary vascular bed,this serpin may play a pivotal role in the pathogenesis of these diseases.
引用
收藏
页码:984 / 991
页数:8
相关论文
共 107 条
[1]
Alessi MC, 2004, ARCH MAL COEUR VAISS, V97, P673
[2]
ANDREASEN PA, 1986, J BIOL CHEM, V261, P7644
[3]
Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis [J].
Aso, Yoshimasa .
FRONTIERS IN BIOSCIENCE-LANDMARK, 2007, 12 :2957-2966
[4]
The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin:: Implications for antiangiogenic strategies [J].
Bajou, K ;
Masson, V ;
Gerard, RD ;
Schmitt, PM ;
Albert, V ;
Praus, M ;
Lund, LR ;
Frandsen, TL ;
Brunner, N ;
Dano, K ;
Fusenig, NE ;
Weidle, U ;
Carmeliet, G ;
Loskutoff, D ;
Collen, D ;
Carmeliet, P ;
Foidart, JM ;
Noël, AS .
JOURNAL OF CELL BIOLOGY, 2001, 152 (04) :777-784
[5]
A novel function of plasminogen activator inhibitor-1 in modulation of the AKT pathway in wild-type and plasminogen activator inhibitor-1-deficient endothelial cells [J].
Balsara, Rashna D. ;
Castellino, Francis J. ;
Ploplis, Victoria A. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (32) :22527-22536
[6]
THROMBIN IMMOBILIZED TO EXTRACELLULAR-MATRIX IS A POTENT MITOGEN FOR VASCULAR SMOOTH-MUSCLE CELLS - NONENZYMATIC MODE OF ACTION [J].
BARSHAVIT, R ;
BENEZRA, M ;
ELDOR, A ;
HYAM, E ;
FENTON, JW ;
WILNER, GD ;
VLODAVSKY, I .
CELL REGULATION, 1990, 1 (06) :453-463
[7]
uPAR: A versatile signalling orchestrator [J].
Blasi, F ;
Carmeliet, P .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2002, 3 (12) :932-943
[8]
Reactive oxygen species activate the HIF-1α promoter via a functional NFκB site [J].
Bonello, Steve ;
Zahringer, Christian ;
BelAiba, Rachida S. ;
Djordjevic, Talija ;
Hess, John ;
Michiels, Carine ;
Kietzmann, Thomas ;
Goerlach, Agnes .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2007, 27 (04) :755-761
[9]
Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation - A gene targeting and gene transfer study in mice [J].
Carmeliet, P ;
Moons, L ;
Lijnen, HR ;
Janssens, S ;
Lupu, F ;
Collen, D ;
Gerard, RD .
CIRCULATION, 1997, 96 (09) :3180-3191
[10]
Plasminogen activator inhibitor-1 inhibits prostate tumor growth through endothelial apoptosis [J].
Chen, Shang-Chiung ;
Henry, Dale O. ;
Reczek, Peter R. ;
Wong, Michael K. K. .
MOLECULAR CANCER THERAPEUTICS, 2008, 7 (05) :1227-1236